IOTA Pharmaceuticals Ltd

Brief description
IOTA Pharmaceuticals is a new-style pharmaceutical discovery services company,engaged in the area of discovery programmes and possessing a wealth of discovery knowledge and experience which we place at our clients’ disposal. Much of the R&D behind IOTA has been carried out at the Vrije Universiteit in Amsterdam, which is also a founding investor in the company.

Problem in the market
Sequencing the human genome has opened up new opportunities for drug discovery. For example, the involvement of a particular gene in a disease process makes it possible to design highly potent compounds which selectively target the gene products. Discovery programmes using structure-based design approaches can streamline this process.

How does IOTA Pharmaceuticals Ltd. address the problem? 
IOTA has one of the largest and most varied fragment libraries for initiating discovery programs. In addition, application of advanced rapid screening techniques leads to fast identification of specific, active pharmacophores. IOTA has also considerable experience in developing focused medicinal chemistry approaches based on active fragments and their associated pharmacophores, making the design, synthesis and optimization of early stage leads a relatively rapid and precise process. For more details of their capabilities, see www.iotapharma.com